home / stock / immx / immx news

IMMX News and Press, Immix Biopharma Inc. From 12/18/23

Stock Information
Company Name: Immix Biopharma Inc.
Stock Symbol: IMMX
Market: NASDAQ
Website: immixbio.com
Menu
IMMX IMMX Quote IMMX Short IMMX News IMMX Articles IMMX Message Board
Get IMMX Alerts

News, Short Squeeze, Breakout and More Instantly...
IMMX - BATL, SNCR and BVN are among pre market gainers

2023-12-18 08:17:02 ET Getaround ( GETR ) +85% . Battalion Oil Corp ( BATL ) +82% . Verrica Pharmaceuticals ( VRCA ) +62% . Cardio Diagnostics Holdings ( CDIO ) +45% . Brilliant Acquisition  ( BRLI ) +45% . Northann  ( ...
IMMX - BATL, and TANH among mid-day movers

2023-12-15 13:25:40 ET Gainers: Getaround ( GETR ) +116% . Battalion Oil Corp ( BATL ) +82% . La Rosa Holdings Corp. ( LRHC ) +45% . Verrica Pharmaceuticals ( VRCA ) +37% . Bruush Oral Care ( BRSH ) +36% . NCS Multistage Hold...

IMMX - CAN, TPIC and MOTS among mid-day movers

2023-12-14 12:28:56 ET Gainers: Freight Technologies ( FRGT ) +178% . TPI Composites ( TPIC ) +67% . TriSalus Life Sciences ( TLSI ) +35% . Codexis ( CDXS ) +33% . Canterbury Park Holding Corp ( CPHC ) +33% . Canaan ( CAN ...

IMMX - Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023

100% (10/10) overall response rate (ORR) and 70% (7/10) complete response (CR) rate observed in standard of care (Dara-CyBorD) relapsed/refractory AL Amyloidosis patients with median 6 lines of prior therapy in updated Phase 1/2 data as of December 10, 2023 Best responder duration of response...
IMMX - Immix Biopharma: Seeking Catalysts To Propel Out Of Microcap Status

2023-12-03 02:02:03 ET Summary Immix Biopharma is a biotech company focused on developing CAR-T and other cell-based therapies for cancers and heme disorders. Their most advanced project is NXC-201, a BCMA-targeted CAR-T natural killer cell therapy, which has shown a 95% overall r...

IMMX - Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit

LOS ANGELES, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today announc...

IMMX - Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis

LOS ANGELES, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq:IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company advancing personalized therapies for oncology and immunology, today announce...
IMMX - FDA okays US clinical testing for Immix drug NXC-201

2023-11-21 11:54:51 ET More on Immix Biopharma, Inc. Immix Biopharma: A Mid-To-Late Stage CAR-T Biotech Quietly Gaining Momentum Immix Biopharma climbs on upcoming ASH readout Immix gains FDA orphan drug status for CAR-T therapy Seeking Alpha’s Quant R...

IMMX - Immix granted FDA nod to start U.S. trial for cell therapy

2023-11-21 11:47:03 ET More on Immix Biopharma Immix Biopharma: A Mid-To-Late Stage CAR-T Biotech Quietly Gaining Momentum Immix Biopharma climbs on upcoming ASH readout Immix gains FDA orphan drug status for CAR-T therapy Seeking Alpha’s Quant Rating ...

IMMX - Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing

NEXICART-2 to expand studies of NXC-201 in relapsed/refractory AL Amyloidosis to U.S. sites based on IND clearance 72 patients previously dosed with NXC-201 ex-U.S. First CAR-T program for light-chain (AL) Amyloidosis Favorable tolerability enables expansion into autoimmune indication...
Previous 10 Next 10